Acadia faced a safety controversy earlier this year when a CNN report outlined hundreds of deaths for patients on Nuplazid and the FDA started a safety review of the drug. Now, the agency reports that ...

Most people associate Parkinson’s with tremors and other motor symptoms. But for some, the disease gives rise to something more terrifying, and much more hidden: psychosis. As many as half of the ...

Nuplazid (pimavanserin) is a brand-name medication that healthcare professionals often prescribe to help manage delusions or hallucinations with Parkinson's disease. Prescription drug plans (PDP) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical ...

Acadia's Nuplazid suffered a big loss in July after a late-stage trial as an add-on treatment for schizophrenia fell flat. But that study wasn't Nuplazid's last go at the indication, and now a phase 2 ...

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug’s risks. In response to questioning at a ...

MONDAY, May 2, 2016 -- Nuplazid (pimavanserin) has been approved by the U.S. Food and Drug Administration to treat hallucinations and delusions associated with Parkinson's disease. As many as half of ...

An Estimated 40 Percent of Parkinson’s Disease Patients Have Psychosis SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...